Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Budesonide

Related Products

Hot Products

Basic Information post buying leads Suppliers
Name Budesonide EINECS 257-139-7
CAS No. 51333-22-3 Density 1.27 g/cm3
Solubility Melting Point 221-232 °C (dec.)
Formula C25H34O6 Boiling Point 599.7 °C at 760 mmHg
Molecular Weight 430.59 Flash Point 201.8 °C
Transport Information Appearance white solid
Safety 22-26-36 Risk Codes 20/21/22-36/37/38-40
Molecular Structure Molecular Structure of 51333-22-3 (Budesonide) Hazard Symbols HarmfulXn
Synonyms

Budeson;Respules;16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione;Entocort;Pregna-1,4-diene-3,20-dione,16,17- [butylidenebis(oxy)]-11,21-dihydroxy-,(11a,- 16R)-;Rhinocort;Budesonide (11beta,16alpha);Micronyl;Preferid;(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde;(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione;Cortivent;Prestwick_840;Rhinocort alpha;

 

Specification

1. Introduction of Budesonide
Budesonide is one kind of white crystalline powder or white solid. It is toxic. So the storage environment should be ventilate, low-temperature and dry. The Systematic (IUPAC) name of it is 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione. It belongs to Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Steroid and Hormone.

The Classification Code of it is Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-inflammatory; Autonomic Agents; Bronchodilator agents; Drug / Therapeutic Agent; Glucocorticoids; Hormone; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Human Data; Peripheral Nervous System Agents; Reproductive Effect; Respiratory System Agents.

2. Properties of Budesonide
Physical properties about Budesonide are:
(1)Melting Point: 221-232°C (dec.); (2)Index of Refraction: 1.592; (3)Molar Refractivity: 113.86 cm3; (4)Molar Volume: 336.4 cm3; (5)Surface Tension: 55.2 dyne/cm; (6)Density: 1.27 g/cm3; (7)Flash Point: 201.8 °C; (8)Enthalpy of Vaporization: 102.44 kJ/mol; (9)Boiling Point: 599.7 °C at 760 mmHg; (10)Vapour Pressure: 6.94E-17 mmHg at 25 °C; (11)XLogP3-AA: 2.5; (12)H-Bond Donor: 2; (13)H-Bond Acceptor: 6; (14)Rotatable Bond Count: 4; (15)Tautomer Count: 9; (16)Exact Mass: 430.235539; (17)MonoIsotopic Mass: 430.235539; (18)Topological Polar Surface Area: 93.1; (19)Heavy Atom Count: 31.

3. Structure Descriptors of Budesonide
(1)Canonical SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C
(2)InChIKey: VOVIALXJUBGFJZ-KWVAZRHASA-N
(3)Smiles: C1(C=C[C@@]2([C@H]3[C@H](C[C@@]4([C@@]5([C@H](C[C@@H]4[C@@H]3CCC2=C1)O[C@@H](CCC)O5)C(CO)=O)C)O)C)=O
(4)InChI: InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20-,21?,22+,23-,24-,25+/m0/s1

4. Toxicity of Budesonide

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 subcutaneous 173mg/kg (173mg/kg) GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH

BLOOD: CHANGES IN SPLEEN

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
man TCLo inhalation 34ug/kg (.034mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" Australian and New Zealand Journal of Medicine. Vol. 22, Pg. 511, 1992.
mouse LD50 intraperitoneal 179mg/kg (179mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
mouse LD50 intravenous 124mg/kg (124mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
mouse LD50 oral 4750mg/kg (4750mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
mouse LD50 subcutaneous 53600ug/kg (53.6mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
rat LD50 intraperitoneal 138mg/kg (138mg/kg) BLOOD: CHANGES IN SPLEEN

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
rat LD50 intravenous 98900ug/kg (98.9mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
rat LD50 oral > 3200mg/kg (3200mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 1985.
rat LD50 subcutaneous 58400ug/kg (58.4mg/kg) BLOOD: CHANGES IN SPLEEN

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Kiso to Rinsho. Clinical Report. Vol. 19, Pg. 4377, 19

5. Physical Properties of Budesonide

Physical Property Value Units Temp (deg C) Source
Melting Point 226 dec deg C   EXP
log P (octanol-water) 2.180 (none)   EST
Atmospheric OH Rate Constant 1.28E-10 cm3/molecule-sec 25 EST

6. Safety information of Budesonide
Hazard Codes: HarmfulXn
Risk Statements: 40-36/37/38-20/21/22 
R40: Limited evidence of a carcinogenic effect. 
R36/37/38: Irritating to eyes, respiratory system and skin. 
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed.
Safety Statements: 22-36-26 
S22: Do not breathe dust. 
S36: Wear suitable protective clothing. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
WGK Germany: 3
RTECS: TU3723000
Poison by subcutaneous, intravenous, and intraperitoneal routes. Moderately toxic by ingestion. An experimental teratogen. Other experimental reproductive effects. When heated to decomposition it emits acrid smoke and fumes.

7. Uses of Budesonide
Budesonide (CAS NO.51333-22-3) is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. It is also used for Crohn's disease (inflammatory bowel disease). It is used as an antiinflammatory agent. Budesonide is a non-halogenated glucocorticoid related to triamcinolone hexacetonide.As a pharmaceutical raw material, it can be used in the medicine.

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields